EGFR and intrahepatic cholangiocarcinoma: Moreover, EGFR mutations (E709K, L747–P753 delins, V786M) were identified in 7.4% (6/81) of patients with ICC, and a higher EGFR mutation rate (5/38, 13.2%) was detected in patients with ICC who had chronic advanced liver disease relative to those with normal livers (1/43, 2.3%) [106].